CAJ | 학술논문

目的研究弥漫大B细胞淋巴瘤(DLBCL)MTAP、CDKN2A和CDKN2B基因的表达及其临床意义.方法以实时定量聚合酶链反应(PCR)方法检测40例DLBCL及19例淋巴结反应性增生组织中MTAP、CDKN2A和CDKN2B基因的表达情况,结合临床特征进行分析,并进行随访.结果 DLBCL组MTAP、CDKN2A和CDKN2B基因表达水平较淋巴结反应性增生组降低,差异有统计学意义(P值分别为0.024、0.044和0.047);三者表达均与Ann Arbor临床分期相关(P值分别为0.004、0.001和0.027);与患者的性别、年龄、淋巴结外病变累及、ECOG体力评分、骨髓累及、血清乳酸脱氢酶水平均无明显相关(均P＞0.05).其中MTAP与CDKN2A基因表达情况还与B症状(P值分别为0.003和0.028)和国际预后指数(IPI)相关(P值分别为0.001和0.011).此外,生存分析结果显示,MTAP、CDKN2A和CDKN2B基因表达水平与患者总生存期相关(P值分别为0.022、0.019和0.042).结论 MTAP、CDKN2A和CDKN2B基因在DLBCL中呈低水平表达,与疾病进展和患者预后有关,可作为反映其生物学行为和评估患者临床疗效的分子标志物.
목적 연구미만대B세포림파류(DLBCL)MTAP、CDKN2A화CDKN2B기인적표체급기림상의의.방법 이실시정량취합매련반응(PCR)방법검측40례DLBCL급19례림파결반응성증생조직중MTAP、CDKN2A화CDKN2B기인적표체정황,결합림상특정진행분석,병진행수방.결과 DLBCL조MTAP、CDKN2A화CDKN2B기인표체수평교림파결반응성증생조강저,차이유통계학의의(P치분별위0.024、0.044화0.047);삼자표체균여Ann Arbor림상분기상관(P치분별위0.004、0.001화0.027);여환자적성별、년령、림파결외병변루급、ECOG체력평분、골수루급、혈청유산탈경매수평균무명현상관(균P＞0.05).기중MTAP여CDKN2A기인표체정황환여B증상(P치분별위0.003화0.028)화국제예후지수(IPI)상관(P치분별위0.001화0.011).차외,생존분석결과현시,MTAP、CDKN2A화CDKN2B기인표체수평여환자총생존기상관(P치분별위0.022、0.019화0.042).결론 MTAP、CDKN2A화CDKN2B기인재DLBCL중정저수평표체,여질병진전화환자예후유관,가작위반영기생물학행위화평고환자림상료효적분자표지물.
Objective To investigate the clinical significance of MTAP, CDKN2A and CDKN2B gene expression in diffuse large B-cell lymphoma (DLBCL). Methods MTAP, CDKN2A and CDKN2B gene expression were assessed by Real-time quantitative PCR in 40 cases of DLBCL and 19 cases of reactive hyperplasia. The clinical and follow-up data were also collected. Results Comparing with reactive hyperplasia, MTAP, CDKN2A and CDKN2B gene expression were decreased in DLBCL group (P = 0.024,0.044 and 0.047, respectively). Low-expression of all the three genes were associated with advanced Ann Arbor stage (P=0.004, 0.001 and 0.027, respectively). No obvious difference were observed according to gender, age, the number of the extra-nodal infiltration, ECOG score, bone marrow involvement and serum LDH level (P ＞0.05). MTAP and CDKN2A gene expression were associated with B symptoms (P =0.003 and 0.028, respectively) and IPI scores (P =0.001 and 0.011, respectively). With regard to survival rates,MTAP, CDKN2A and CDKN2B gene expression were significantly associated with OS (P =0.022, 0.019 and 0.042, respectively). Conclusion MTAP, CDKN2A and CDKN2B gene expression in DLBCL were decreased and related to disease progression and prognosis. They could be considered as biomarkers to evaluate biological behavior and clinical outcome of DLBCL patients.